Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
about
Current concepts in the pathophysiology and treatment of aplastic anemiaAdvances in sickle cell therapies in the hydroxyurea eraFludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working PartyHematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria.Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.Chronic GVHD manifesting as parotitis after allogeneic hematopoietic SCT.Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia.Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigensCTLA4-Ig prevents alloantibody production and BMT rejection in response to platelet transfusions in mice.Mechanisms of alloimmunization and subsequent bone marrow transplantation rejection induced by platelet transfusion in a murine model.Clinical management of aplastic anemia.Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.Clinical implications of chimerism after allogeneic hematopoietic stem cell transplantation in children with non-malignant diseasesConditioning with rabbit versus horse ATG dramatically alters clinical outcomes in identical twins with severe aplastic anemia transplanted with the same allogeneic donorNonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.Evolving hematopoietic stem cell transplantation strategies in severe aplastic anemia.Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity.Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation studyParoxysmal nocturnal hemoglobinuria and myelodysplastic syndromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failureTransfusion of minor histocompatibility antigen-mismatched platelets induces rejection of bone marrow transplants in mice.Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen.Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation.Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning.Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling.Matched sibling donors versus alternative donors in allogeneic hematopoietic stem cell transplantation for pediatric severe aplastic anemia in México.HLA-matched sibling transplantation with BM and CD34(+)-purified PBSCs in adult patients with high-risk severe aplastic anemia to overcome graft rejection without an increase in GVHD.Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.The use of a fludarabine-based conditioning regimen in patients with severe aplastic anemia--a retrospective analysis from three Indian centers.Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.Generation of induced pluripotent stem cells as a potential source of hematopoietic stem cells for transplant in PNH patients.Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia.Reduced-dose cyclophosphamide in combination with fludarabine and anti-thymocyte globulin as a conditioning regimen for allogeneic hematopoietic stem cell transplantation for aplastic anemia.Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia.Effective eculizumab therapy followed by BMT in a boy with paroxysmal nocturnal hemoglobinuria.
P2860
Q24685812-62C47764-A7E2-4244-B006-759ABED5DA1FQ28088552-B556C0AD-447B-4437-9F67-EFAF6FCE1625Q33886206-5551D987-7600-4F0F-AB86-21A56BC0BBB3Q33886212-5D05EFD9-2BE8-49B8-8237-945D4CBAEE93Q34148715-0908CE05-E1C6-4ABF-A968-CBCA56269315Q34228345-E05516BB-2C0B-45A3-8E65-B60EAD3406D9Q34427075-64AE4540-B3CE-40DD-8767-D57BC4247843Q34545908-7549AC2C-75A8-4844-87A4-6EDB2E06CCDFQ34824419-35703E27-85BE-4BA6-BA87-F5B6794D7DB5Q34824540-13193173-3B7C-420B-89C1-49AB0F702006Q34976550-1B37A627-FA1F-4F9B-8564-F8ABFA5690D6Q35112372-5D35FB0D-B433-4B70-B519-D8210B85BD12Q35153756-74FF6E92-D841-42BF-B597-D62D1AFFB499Q35676039-C05566DB-2FF9-4C74-84E2-C9D10976615AQ35805248-A1D8D69A-113D-4070-8485-863BC4835567Q36423553-D5F1D0B5-736C-4D44-9643-45BC60E22930Q36497220-02FB2B52-85A8-46A1-BF49-FABC23ECE682Q36548685-EC52F9B5-9082-4281-9F67-9F83035F67C0Q36769277-42C28A4F-F6A6-4289-B1D7-FB31F5C05CB0Q36884109-1F0C5662-42F8-41ED-84D0-1CD124950F62Q37059401-2AD90C29-9761-4102-B65B-DF6B773658B6Q37328417-181DC73E-935F-497C-B1E1-0CB5E1F08154Q37334992-4D6D1936-36BC-4C4D-BBB5-B4C7C88AB1BBQ37390291-B90EEC2C-EC07-4930-9868-2FAB49A79020Q38065878-E47F7F17-2155-4713-981F-78025296A43CQ39972680-20937E9B-E94F-4C66-9916-215C1C6D856FQ41584606-CF9DCED1-B8A0-4546-9088-E73966D5B709Q43198283-71CD3477-85C2-4301-9B6E-EB8E6B8CFE29Q43418954-F96C61D6-6C12-4114-8F3F-C230D256B9BBQ45764430-50AE46A4-E070-462D-84AA-749B1843CC8BQ46200213-0DB5DFA2-8DB1-4A03-ADB5-D14B1671EFAEQ47688118-E2B85BDD-9F39-4690-9B43-5FE5273E909AQ48840457-6F662862-4989-4165-A8FC-F0DC113ABF20Q53005441-2C169377-DAD4-4D8A-A8A9-C5AFB16FAE8DQ53460735-BF98D483-43EA-44B3-B926-57E5056DB2C0Q54711241-A87D477D-6F8C-4F9E-95E7-FB53A2E0845E
P2860
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Overcoming graft rejection in ...... opoietic cell transplantation.
@en
Overcoming graft rejection in ...... opoietic cell transplantation.
@nl
type
label
Overcoming graft rejection in ...... opoietic cell transplantation.
@en
Overcoming graft rejection in ...... opoietic cell transplantation.
@nl
prefLabel
Overcoming graft rejection in ...... opoietic cell transplantation.
@en
Overcoming graft rejection in ...... opoietic cell transplantation.
@nl
P2093
P2860
P1476
Overcoming graft rejection in ...... opoietic cell transplantation.
@en
P2093
A John Barrett
Colleen Dorrance
Igor Espinoza-Delgado
J Philip McCoy
Nancy Geller
Neal S Young
Ramaprasad Srinivasan
Richard W Childs
Yoshiyuki Takahashi
P2860
P304
P356
10.1111/J.1365-2141.2006.06019.X
P407
P577
2006-05-01T00:00:00Z